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Clinical Practice Guidelines.
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Benoit Colinet, Didier Dequanter, Anna Efremidis, Marie-Chantal Florin, 
Vicente Giner, StefaneJouveshom, George Koumakis Jean-Jacques Lafitte, 
Jacques Lecomte, Jean Lemaitre, Ingrid Louviaux, Celine Mascaux, 
Anna-Pascale Meert, Vincent Ninane, Michel Richez, Jean-Paul Sculier, 
Bruno Stach, Michael M. Vaslamatzis, Patricia Wackenier
A B S T R A C T
The present guidelines on the management of resectable non-small cell lung cancer 
(NSCLC) were formulated by the (ELCWP) in April 2005. They aim in answering the 
following eleven questions: 1) Is surgery the best therapy for a potentially resectable 
cancer? 2) How is complete resection defined? 3) Is systematic lymph node dissection 
necessary during surgery? 4) What is the role of radiotherapy after complete resec-
tion? 5) Should adjuvant or neoadjuvant chemotherapy be administered in clinical 
stages I or II? 6) Should adjuvant chemotherapy be administered in pathological 
stages I or II? 7) Is adjuvant therapy advisable after complete resection for pathologi-
cal stage IIIA N2? If yes, of what type: chemotherapy, radiotherapy or chemotradio-
herapy? 8) What are the indications for surgery after induction treatment, in clinical 
stages IIIA or IIIB? 9) In clinical stages IIIA or IIIB, is preoperative therapy required 
and of what type? 10) What type of treatment is indicated after an incomplete surgical 
resection? 11) What is the best regimen for (neo)adjuvant chemotherapy?
I N T R O D U C T I O N
European Lung Cancer Working Party (ELCWP) is a cooperative research group, 
actively engaged in the thoracic oncology field, for more than 25 years now. It has con-
ducted and still continues to conduct a number of academic clinical trials for various 
stages and histological types of lung cancer. Published trials can be found at the Group’s 
website (www.elcwp.org). The Group is also interested in evidence-based medicine and 
it has published, so far, a number of systematic reviews and meta-analyses. In recent 
years, many European countries created, by legal disposition, oncological networks 
and cancer care programmes. Members of ELCWP have therefore to integrate clinical 
research trials of the Group into developed local programmes. In order to optimise 
this enterprise and keep a common research programme, the members decided to 
formulate consensus clinical practice guidelines based on the available literature.
The following is the first of a series of five articles, reporting clinical practice 
CLINICAL PRACTICE GUIDELINES
Evangelismos Hospital, Department 
of Medical Oncology, Athens, Greece, 
Institut Jules Bordet, Brussels, 
Belgium, Hôpital de Hayange, 
Hayange, France, Clinique St-Joseph, 
Gilly, Belgium, Hellenic Cancer 
Institut, Saint-Savas Hospital, 
Athens, Greece,Centre Hospitalier de 
Douai, Douai, France, Hospital de 
Sagunto, Valence, Spain, CHI Poissy 
St-Germain, St-Germain-en-Laye, 
France, CHRU de Lille, Hôpital 
Albert Calmette, Lille, France, Hôpital 
Ambroise Paré, Mons, Belgium, CH 
Peltzer-La Tourelle, Verviers, Belgium, 
Hôpital Saint-Pierre, Brussels, 
Belgium, CHR St-Joseph-Warquignies, 
Boussu, Belgium, Cabinet de 
Pneumologie, Anzin, France
KEY WORDS: guidelines, 
non-small cell lung cancer, surgery, 
adjuvant chemotherapy, neoadjuvant 
chemotherapy
HOSPITAL CHRONICLES 2006, 1(1): 52–61
Address for correspondence:
Professeur JP SCULIER, 
Institut Jules Bordet
1 rue Héger-Bordet, B-1000 Bruxelles
tél (32) 2 5413185
fax (32) 2 5343756
e-mail: sculier@bordet.be
52
HOSPITAL CHRONICLES 1(1), 2006 EUROPEAN LUNG CANCER WORKING PARTY CLINICAL PRACTICE GUIDELINES
53
guidelines for lung cancer, formulated by the European 
Lung Cancer Working Party (ELCWP). These articles will 
consecutively deal with the treatment of early (resectable) 
stages of non-small cell lung cancer (NSCLC), locoregion-
ally advanced NSCLC, metastatic NSCLC and small-cell lung 
cancer (SCLC) limited and extensive stages.
T R E A T M E N T  O F  E A R L Y  ( R E S E C T A B L E )  
S T A G E S  O F  N O N - S M A L L  C E L L  L U N G  
C A N C E R  
M E T H O D O L O G Y
During a meeting of the Group, organised in Mons, 
Belgium, in September 2004, and after an extensive discus-
sion, a consensus was reached among members to base the 
formulation of guidelines of treatment of early (resectable) 
stages non-small lung cancer on eleven predefined essential 
questions:
 1. Is surgery the best therapy of a potentially resectable lung 
cancer?
 2. What constitutes a complete resection?
 3. Is a systematic lymph node dissection necessary?
 4. What is the role (if any) of radiotherapy after complete 
resection?
 5. Is adjuvant or neoadjuvant chemotherapy indicated in 
clinical stage I or II?
 6. Should adjuvant chemotherapy be administered in patho-
logical stage I or II?
 7. Should adjuvant therapy be advised after complete resec-
tion for pathological stage IIIA N2, and if yes, what type: 
chemotherapy, radiotherapy or radiochemotherapy?
 8. What are the indications for surgery after induction treat-
ment in clinical stage IIIA or IIIB? 9) In clinical stage 
IIIA or IIIB, if surgery is considered, is induction therapy 
required, and if yes, of what type?
 10. What should be the postoperative treatment after incom-
plete surgical resection,
 11. Which regimen should be advised as adjuvant or neoad-
juvant chemotherapy?
For the purpose of answering the above questions, a 
thorough review of several sources of data published in the 
literature was undertaken. It included clinical trials, system-
atic reviews and meta-analyses, and guidelines from medical 
societies and scientific groups. Literature was identified and 
analysed by the evidence-based medicine group of the ELCWP. 
Where necessary, aggregation of randomised clinical trials 
was performed by the meta-analysis method as previously 
described [1-4]. The quality of published guidelines was as-
sessed using the AGREE instrument [5-8], allowing elimina-
tion of the worst and use of the best of them as sources for 
the formulation of the ELCWP guidelines. Accordingly, the 
following guidelines were selected: ASCO (American Society 
of Clinical Oncology) guidelines [9,10], BTS (British Thoracic 
Society) guidelines [11], Cancer Care Ontario Practice Guide-
lines [12] (www.cancercare.on.ca/access_PEBC.htm), Royal 
College of Radiologists guidelines [13], American College 
of Chest Physicians (ACCP) guidelines [14] and FNCLCC 
(Fédération Nationale des Centres de Lutte contre le Cancer) 
guidelines [15]. Our selection was based on the results of a 
prior assessment of the literature performed by the ACCP 
[16], complemented by our own analysis, performed by using 
the AGREE instrument, of other guidelines not considered 
by ACCP. This approach allowed us to include the FNCLCC 
and ACCP guidelines.
The text of our recommendations produced in the above 
way has been presented, actively debated and definitively ap-
proved by the Group in a final meeting, in Brussels, in April 
2005.
Q U E S T I O N  1 :  I S  S U R G E R Y  T H E  B E S T  
T H E R A P Y  F O R  A  P O T E N T I A L L Y  
R E S E C T A B L E  L U N G  C A N C E R ?
This question has already been addressed in various 
published guidelines. In 2000, the FNCLCC recommended 
surgery for stages I and II NSCLC as well as for some T4N0 
[17]. It stated as reference values, a less than 2% operative 
mortality for lobectomies and less than 6% for pneumonec-
tomies. Surgery was considered optimal therapy for local 
control in stage IIIA N2. In 2001, the BTS published, similar 
guidelines for stages I and II and some stages T4N0-1 [11]. It 
proposed surgery in combination with chemotherapy for some 
stages IIIA. According to BTS, only 5 to 10% of patients with 
stage I and II tumours should be considered inoperable. A 
similar approach was proposed, in 2001, by the Royal College 
of Radiologists [13]. Finally, in 2003, the ACCP recommended 
surgery alone and lobectomy or sleeve lobectomy, when pos-
sible, rather than pneumonectomy, for stages I [18] and II [19]. 
It proposed surgery only for stages III [20,21] as well as stages 
T4 N0-1 by virtue of satellite nodule.
For evident ethical reasons, no randomised controlled 
trials exist demonstrating the efficacy of surgery alone. The 
level of evidence is based on historical data [22]: The first 
lobectomies were performed in 1920 by Sauerbruck, a well-
known German surgeon whose reputation soon waned as a 
result of his connections to Gebhart, a famous orthopaedist 
but also an SS General charged with the execution of medical 
experiments in the concentration camps. The first pneumo-
nectomies were performed in the United States by Graham 
in 1930 while in 1950, Churchill from Harvard University 
reported a 12% 5 year survival for pneumonctomy and 19% 
for lobectomy. Today‘s cure rates are much higher. Mountain 
referring to the series on which the current staging system of 
lung cancer is based [23] has reported, 5 year-survival rates 
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of 61% in cIA stage (67% for pathological stages), 38% in cIB 
(57%), 34% in cIIA (55%), 24% in cT2N1 (39%) and 22% in 
cT3 N0 (38%).
More limited resections than lobectomy, such as segmen-
tectomy and wedge resection, are possible, They have been 
tested in 2 randomised trials: The first, conducted by the 
Lung Cancer Study Group, in North America included 247 
patients with clinical stage T1 N0 [24]. It has shown better 
results after lobectomy than after wedge resection, both in 
terms of locoregional relapses (p=0.008) and of 5 year survival 
(p=0.08). The second randomised trial including stage IA 
patients compared lobectomy using classical surgery versus 
video-assisted surgery [25]. It did not show significant dif-
ference between the two arms but because of the limited size 
of the study (100 patients) confirmation of results by further 
studies is required. A systematic review of the literature [26] 
showed that “sleeve” lobectomy, whenever possible, should be 
preferred instead of pneumonectomy because of better results 
in terms of survival and quality of life.
For carcinoma in situ (CIS) and microinvasive squamous 
cell carcinoma, the FNCLCC, the Royal College of Radi-
ologists and the ACCP recommend endoscopic treatment 
(cryotherapy, photochemotherapy, electrocoagulation, brachy-
therapy) as first-line therapy [13,27]. In patients with stages I 
and II tumours, not suitable for surgery, the FNCLCC and the 
Royal College of Physicians recommend elective radiotherapy 
[27]. The ACCP proposes this approach only for stage I.
E L C W P  G U I D E L I N E S :
For stages I and II, treatment must at least include surgery 
(level of evidence: retrospective and prospective operated pa-
tients series); operation should remain an option in stage III. 
In order to improve cure rates, (neo)adjuvant chemotherapy 
is advisable (see questions 5 and 6).
If the patient cannot be operated on for other medical 
reasons or refuses surgery, then elective radiotherapy with 
or without chemotherapy is a valid option (level of evidence: 
retrospective series).
In case of CIS or microinvasive squamous cell carcinoma, 
curative endoscopic therapy (cryotherapy, photochemother-
apy, electrocoagulation, brachytherapy) might be used in the 
context of a clinical trial with a very close follow-up but surgery 
remains the standard first-line treatment (level of evidence: 
prospective and retrospective series of patients).
Q U E S T I O N  2 :  W H A T  C O N S T I T U T E S  
A  C O M P L E T E  R E S E C T I O N ?
There is no published guidelines on this topic. The ACCP 
[18] defines only the type of resection (lobectomy, segmentec-
tomy, wedge resection).
The IASLC (International Association for the Study of 
Lung Cancer) in the context of the International Staging Com-
mittee (including two ELCWP members) has commissioned 
a sub-group to elaborate on the terms complete resection, 
incomplete resection and uncertain resection. These defini-
tions, when finalised, will be useful.
E L C W P  G U I D E L I N E S :
Resection definition to be proposed by IASLC should be 
used in order to facilitate comparison of the results between 
different studies.
Q U E S T I O N  3 :  I S  A  S Y S T E M A T I C  L Y M P H  
N O D E  D I S S E C T I O N  N E C E S S A R Y ?  
There are three published guidelines on this topic. Ac-
cording to FNCLCC, homolateral mediastinal dissection is 
recommended. BTS also suggests the performance of nodal 
dissection in every case, mainly for the purpose of establish-
ing a precise pathological staging [11]. According to ACCP, 
a systematic lymph node dissection has to be performed in 
every patient [18,19].
There are three published and two ongoing randomised 
trials comparing systematic dissection with lymph nodes 
sampling. Izbicki randomising 182 patients and Passlick ran-
domising 94 patients, have both failed to show improvement 
of survival or of local relapse rate [28]. On the contrary, Wu, 
in a much larger study including 471 patients randomised 
between mediastinal lymphadenectomy and no mediastinal 
lymphadenectomy, demonstrated a significant improvement 
in 5 year-survival (48.2% versus 37%; p<0.001) and in local 
relapse rate (2.9% versus 4.8%) favouring lymphadenectomy 
[29].
E L C W P  G U I D E L I N E S :
Mediastinal lymphadenectomy has to be systematically 
performed in order to achieve a precise pathological staging, 
a very important information for prognosis and choice of fur-
ther therapy (level of evidence: experts opinion and published 
guidelines consensus).
Q U E S T I O N  4 :  W H A T  I S  T H E  R O L E  
( I F  A N Y )  O F  R A D I O T H E R A P Y  A F T E R  
C O M P L E T E  R E S E C T I O N ?
This question has been addressed in various guidelines. 
The FNCLCC reports that radiotherapy has no role in stage 
I and II. In stage III, it emphasises that radiotherapy with 
modern techniques may have a place [15]. According to the 
BTS and the Royal College of Physicians, thoracic irradiation 
is not recommended after complete resection [11,13]. Cancer 
Care Ontario recommends radiotherapy only for stage IIIA, 
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based on a case by case decision, emphasizing that the benefit 
in terms of survival has not been demonstrated. Finally, the 
ACCP recommends radiotherapy for stages II and III but only 
to reduce the risk of local relapse [19,20].
The evidence against post-operative chest irradiation 
after complete resection in early stages, comes from PORT 
meta-analysis based on nine randomised trials and showing a 
deleterious effect of radiotherapy [30,31]. The level of evidence 
is thus high but it should be noted that in all nine studies old 
radiotherapeutic techniques were used. 
E L C W P  G U I D E L I N E S :
Today, postoperative radiotherapy is not recommended 
for stages I and II completely resected tumours (level of 
evidence: meta-analysis of 9 trials). Nevertheless, postopera-
tive irradiation has to be further investigated using modern 
techniques.
For resected stage III disease, radiotherapy is advocated in 
combination with adjuvant chemotherapy (see question 7).
Q U E S T I O N  5 :  I S  A D J U V A N T  O R  N E O A D -
J U V A N T  C H E M O T H E R A P Y  I N D I C A T E D  
I N  C L I N I C A L  S T A G E  I  O R  I I ?
For clinical stages IB-II, the FNCLCC [17] recommends 
neoadjuvant (also called primary or induction) chemotherapy 
as an option. However, the Royal College of Physicians [13] 
and ACCP [18-19] recommend it only in the context of ran-
domised clinical trials.
In the literature, there is no randomised controlled trial, 
comparing surgery alone with surgery followed by adjuvant 
chemotherapy for clinical stage I or II. On the contrary, there 
is some data about neoadjuvant chemotherapy from a sub-
group analysis of a phase III randomised trial conducted by 
Depierre in France [32] using MIP combination (mitomycine 
+ ifosfamide + cisplatin). For stages IB and II (N0, N1), there 
is a significant improvement of survival and cure rate.
E L C W P  G U I D E L I N E S :
For clinical stages IB and II, neoadjuvant chemotherapy 
can be advised, preferably in the context of a clinical trial (level 
of evidence: sub-group analysis of a prospective randomised 
controlled trial). Outside a trial, MIP combination should 
be used because this is the only regimen shown effective in 
controlled data.
For stage IA (small size tumours), due to a lack of con-
trolled studies, there is no evidence for administration of 
preoperative chemotherapy.
For resected stage IB or II tumours, adjuvant chemo-
therapy is recommended if the clinical stage is confirmed by 
the pathological stagee (see question 6).
Q U E S T I O N  6 :  S H O U L D  A D J U V A N T  
C H E M O T H E R A P Y  B E  A D M I N I S T E R E D  
I N  P A T H O L O G I C A L  S T A G E  I  O R  I I ?
The available guidelines of FNCLCC [17], Royal College 
of Radiologists [13] and ACCP [18-19] recommend adjuvant 
chemotherapy for resected stage I or II tumour only in the 
context of a clinical trial. 
As summarised in table I, there are multiple randomised 
trials published on the topic We have identified eight trials 
[33,34-40] specifically performed in stage I and/or II, includ-
ing two available as online presentation (wwww.asco.org) 
only [39,40] and four providing sub-group analysis for these 
stages [41-44]. Five of the studies report significant survival 
improvement by chemotherapy with regimens such as cisplatin 
+ adriamycine + cyclophosphamide, cisplatin + etoposide, 
cisplatin + vinorelbine or carboplatin + paclitaxel or UFT. 
Patients with a pathological stage IA were often excluded form 
the randomisation.
Two previous meta-analyses have already shown a survival 
advantage with adjuvant chemotherapy [1,45] and their results 
have been confirmed by two recent meta-analyses [46,47]. 
None separates stages I and II from stage III. A Japanese 
meta-analysis, presented by Hamada at ASCO 2004 meeting 
and available online (www.asco.org/virtualmeeting), shows 
that UFT is associated with an improvement in long-term 
survival with the exception of small size tumours (<2cm). 
For the present guidelines, we have updated our prior meta-
analysis (Berghmans and al, Lung Cancer, in press) and have 
specifically analysed the effect of chemotherapy in stages I 
and II for the trials where data were available in the literature. 
Results are shown in Figure 1 and are in favour of adjuvant 
chemotherapy whether or not the two not fully published trials 
[39,40] are considered.
E L C W P  G U I D E L I N E S :
Cisplatin-based chemotherapy, using one of the regimens 
shown effective in term of cure, is recommended after com-
plete resection of a stage IB or II NSCLC (level of evidence: 
prospective randomised controlled trials and meta-analyses). 
There are not enough data to recommend this approach for 
small-size tumours (stage IA).
Q U E S T I O N  7 :  S H O U L D  A D J U V A N T  
T H E R A P Y  B E  A D V I S E D  A F T E R  
C O M P L E T E  R E S E C T I O N  F O R  
P A T H O L O G I C A L  S T A G E  I I I A  N 2 ,  
A N D  I F  Y E S ,  O F  W H A T  T Y P E :  
C H E M O T H E R A P Y ,  R A D I O T H E R A P Y  
O R  R A D I O C H E M O T H E R A P Y ?
Published guidelines from ACCP [20], BTS [11] and the 
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Ontario Practice [12] acknowledging a lack of demonstrated 
benefit in survival, recommends a case by case decision.
There are only two randomised trials specifically in stage 
IIIA, testing a cisplatin + vindesine regimen after a resection 
considered as complete [48,49]. Both failed to show survival 
improvement. There are also five sub-group analyses of global 
trials (table II) testing adjuvant chemotherapy [41-44,50]. Two 
were associated with a benefit [41,44] using cisplatin-based 
regimens.
Apart from our own, none of the published meta-analyses 
refers specifically to the results for stage III. Five studies re-
port aggregated data (Figure 2). Despite a trend in favour of 
adjuvant chemotherapy, statistical significance is not reached. 
A significant heterogeneity is present.
E L C W P  G U I D E L I N E S :
The presently available data do not allow the recommenda-
tion of adjuvant chemotherapy in every patient. Further trials 
are needed, testing the effect of the addition of chemotherapy 
to irradiation and assessing the impact of various cytotoxic drug 
regimens. Today, outside the context of a clinical trial, therapeu-
TABLE I. Results of randomised clinical trials testing adjuvant chemotherapy in pathological stages I and II.
reference n stage control arm 5 year  adjuvant 5 year p Stages 
    survival arm survival  I & II
SPECIFIC RANDOMISED TRIALS
Niiranen, 1992 [33] 110 T1-3 N0 - (56 pts) 56% CAP (54 pts) 67% 0.05
Feld, 1993 [35] 269 T1N1 or T2N0 - (133 pts) NA CAP (136 pts) NA NS
Wada, 1999 [62] 226 I - II  - (116 pts) 71.1% CDDP-MMC-VDS 76.8% NS
     then UFT (109 pts)
Mineo, 2001 [34] 66 IB (T2N0) - (33 pts) 45% CDDP + VP16 (33 pts) 63% 0,04
Endo, 2003 [37] 221 T1-2 & N0-1 - (110 pts) 75% UFT 2 years (109 pts) 79% NS
Kato, 2004 [38] 980 I (adenoc)  - (488 pts) 85% UFT (491pts) 88% 0.047
Strauss, 2004 [39] 344 IB (T2N0) - (171 pts) 59% Paclitaxel – Carboplatine
    (4 years) (173 pts) 71% 0.028
Winton, 2004 [40] 482 IB - II - (239 pts) 54% CDDP – VNR (243 pts)  69% 0.012
SUBGROUP ANALYSIS OF RANDOMISED TRIALS
Dautzenberg,  267 I, II, IIIA RT (60%) 19% ADR/CPA-VCR-CDDP 18% NS 0.03
1995 [41] 130 N0N1 (129 pts) 34% (138 pts) 17% 0.03 (deleterious)
 147 N2  6%  19% 0.03
Chubu study, 309 I – III - (154 pts) 58% CDDP-ADR-UFT 62% NS NS
1995 [42]  (III: 25%)   (155 pts)
Scagliotti,  1209 I-IIIA (RT)   (RT) + CDDP-MMC-  0.59 NS
2003 [43]  (IIIA: 28%) (540 pts)  VDS x 3 (548 pts)
IALT, 2004 [44] 1867 I-III RT (free) 40.4% CDDP + (free) VDS, 44.5% 0.03 NS
  (III: 39%) (935pts)  VBL, VNR, VP16 
     (932 pts)
RT: chest irradiation; pts: patients; NS: non significant; NA: non available; CAP: cisplatin + adriamycine + cyclophosphamide; CDDP: cisplatin; 
MMC: mitomycin; ADR: adriamycine; VDS: vindesine; VBL: vinblastine; VNR: vinorelbine: CPA: cyclophosphamide; VP16: etoposide.
FIGURE 1. Meta-analysis of randomised trials testing the fa-
vourable effect of adjuvant chemotherapy in pathological stages 
I and II. (heterogeneity test: p = 0.11; random effect model: HR 
= 0.81 with 95% CI: 0.73 – 0.91).
Royal College of Radiologists [13] advise chemotherapy only 
in the context of a clinical trial. The ACCP recommends chest 
irradiation to improve local control while the Cancer Care 
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tic decision has to be made on a case by case basis. It is highly 
recommended to include such patients into clinical trials.
Q U E S T I O N  8 :  W H A T  A R E  T H E  
I N D I C A T I O N S  F O R  S U R G E R Y  A F T E R  
I N D U C T I O N  T R E A T M E N T  I N  C L I N I C A L  
S T A G E  I I I A  O R  I I I B ?
The majority of published guidelines recommends a surgi-
cal approach only after multidisciplinary discussion and in the 
context of a clinical trial [11,13,17]. For Cancer Care Ontario 
Practice [12], preoperative chemotherapy followed by postop-
erative radiotherapy is recommended if resection is technically 
feasible and planned. According to ACCP [20,21], surgery is 
advisable if the objective is complete resection, the alterna-
tive being radiotherapy except for non N2 Pancoast tumours 
where induction radiochemotherapy is recommended [51]. 
In the latter situation, BTS also recommends a multimodal 
approach.
There is only one published small-size (45 patients) ran-
domised trial testing the feasibility of surgery after induction 
chemotherapy in comparison to radiochemotherapy without 
resection [52].
A large randomised trial (392 patients) has been per-
formed by the American Intergroup and showed no significant 
overall survival advantage for surgery compared with chest 
irradiation alone [53]. For Pancoast tumours, no prospective 
controlled study is available.
E L C W P  G U I D E L I N E S :
Treatment has to be multimodal, including chemotherapy 
and radical local therapy (level of evidence: experts opinion). 
Concerning local therapy, provided that complete resection 
is feasible, the choice between surgery (+radiotherapy) or 
radiotherapy alone will depend on the available facilities. 
Inclusion in clinical trials is highly advisable. For non N2 
Pancoast tumours, induction chemoradiotherapy prior to 
surgery is recommended.
FIGURE 2. Meta-analysis of randomised trials testing adjuvant 
chemotherapy in pathological stage III. Results are in favour of 
treatment without reaching statistical significance (heterogene-
ity test: p = 0.07; random effect model: HR = 0.85 with 95% 
CI: 0.69 – 1.04).
TABLE II. Results of randomised clinical trials testing adjuvant chemotherapy in pathological stages III. 
reference n stage control arm 5 year  adjuvant 5 year p Stages III
   arm survival arm survival
SPECIFIC RANDOMISED TRIALS
Ohta, 1993 [48] 181 IIIA -(91 pts) 41% CDDP-VDS (90 pts) 35% NS
Tada, 2004 [49] 119 pN2 -(60 pts) 36.1% CDDP-VDS x 3 (59 pts) 28.2% 0.89
  complete
  resection
SUBGROUP ANALYSIS OF RANDOMISED TRIALS
Dautzenberg, 267 I, II, IIIA RT (60%) 19% ADR/CPA-VCR- 18% NS 0.03
1995 [41] 130 N0N1 (129 pts) 34% CDDP (138 pts) 17% 0.03
 147 N2  6%  19% 0.03
Chubu study,  309 I – III -(154 pts) 58% CDDP-ADR-UFT 62% NS NS
1995 [42]  (III: 25%)   (155 pts)
Keller, 2000 [50] 488 II-IIIA RT (50,4 Gy) NA RT + CDDP- NA 0.56 NS
  (IIIA: 58%) (242 pts)  VP16 x 4 (246 pts)
Scagliotti, 2003 [43] 1209 I-IIIA (RT)   (RT) + CDDP-MMC-  0.59 NS
  (IIIA: 28%) (540 pts)  VDS x 3 (548 pts)
IALT, 2004 [44] 1867 I-III RT (free) 40.4% CDDP + (free) VDS,  44.5% 0.03 S
  (III: 39%) (935pts)  VBL, VNR, VP16 (932 pts)
RT: thoracic radiotherapy; pts: patients; NS: non significant; NA: non available; CDDP: cisplatin; MMC: mitomycin; ADR: adriamycine; VDS: 
vindesine; VBL: vinblastine; VNR: vinorelbine: CPA: cyclophosphamide; VP16: etoposide.
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Q U E S T I O N  9 :  I N  C L I N I C A L  S T A G E  I I I A  
O R  I I I B ,  I F  S U R G E R Y  I S  C O N S I D E R E D ,  
I S  I N D U C T I O N  T H E R A P Y  R E Q U I R E D ,  
A N D  I F  Y E S ,  O F  W H A T  T Y P E ?
Many published guidelines (FNCLCC, BTS, Royal 
College of Radiologists and AACP) advocate neoadjuvant 
chemotherapy in this situation with patients inclusion in a 
clinical randomised trial [11,13,17,20,21]. Cancer Care On-
tario Practice recommends preoperative chemotherapy and 
postoperative radiotherapy [12].
The level of evidence consists of a series of small ran-
domised trials mainly performed in stage IIIA [54-59] and 
of the sub-group analysis of Depierre’s study [32]. All the 
data are summarised in table III. There are only two trials 
reporting statistically significant results in favour of induc-
tion chemotherapy. The ELCWP meta-analysis shows, in a 
significant heterogeneity context, a non significant trend in 
favour of induction chemotherapy (Figure 3).
E L C W P  G U I D E L I N E S :
Induction chemotherapy complemented by postoperative 
radiotherapy and administered in the context of a clinical trial 
is highly recommended (level of evidence: experts opinion).
Q U E S T I O N  1 0 :  W H A T  S H O U L D  B E  T H E  
P O S T O P E R A T I V E  T R E A T M E N T  A F T E R  
I N C O M P L E T E  S U R G I C A L  R E S E C T I O N ?
FNCLCC guidelines advocate full-dose external irra-
diation only for stage T3 N1 [17] while the Royal College of 
Radiologists and the ACCP recommend the same approach 
in every case [13,20].
There is only one randomised study on the above topic 
performed in the eighties [60]. It compared radiotherapy 
with or without chemotherapy using cisplatin + adriamycine 
+ cyclophosphamide. Results did not show a difference in 
terms of survival.
E L C W P  G U I D E L I N E S :
These patients must be treated by radiochemotherapy 
as unresectable disease (level of evidence: experts opinion). 
If resection is incomplete at microscopic level, the patient 
should be reoperated or otherwise irradiation should be 
administered.
FIGURE 3. Meta-analysis of randomised trials testing neoadju-
vant chemotherapy in clinical stage IIIA. Results are in favour 
of treatment without reaching statistical significance (heteroge-
neity test : p = 0.02; random effect model: HR = 0.65 with 95% 
CI: 0.41 – 1.04).
TABLE III: R-esults of randomised clinical trials testing neoadjuvant chemotherapy in clinical stage IIIA. 
Reference Treatment n pts IIIA N2 T3 T3 N0-1 RO MS (month) p
SPECIFIC RANDOMISED TRIALS
Pass, 1992 [54] 1. CDDP-VP16 13 13 13 0 0 62% 29 NS
 2. Control 14 14 14 0 0 - 16
Rosell, 1994 [55,56] 1. MMC-Ifo-CDDP(3x) 
  then surgery (+RT) 30 26 25 13 5 53% 26 S
 2. surgery (+RT) 30 21 19 16 11 - 8
Roth, 1994 [57,58] 1. CPA-VP16- CDDP(6x) 
  then surgery (+RT if incomplete) 29 20 20 12 6 35% 64 S
 2. surgery (+RT if incomplete) 32 24 22 15 10 - 11
Nagai, 2003 [59] 1. CDDP-VDS (3x) then surgery 31 31 31 3 0 28% 17 NS
 2. surgery 31 31 31 3 0 77% 16
SUBGROUP ANALYSIS OF RANDOMISED TRIALS
Depierre, 2001 [32] 1. MMC-Ifo-CDDP x 2 then surgery 179 92 92   NA NA NS
 2. surgery  176 75 75   - NA
RT: thoracic radiotherapy; pts: patients; S: significant; NS: non significant; NA: non available; CDDP: cisplatin; MMC: mitomycin; Ifo: ifosfamide; 
VDS: vindesine; CPA: cyclophosphamide; VP16: etoposide.
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Q U E S T I O N  1 1 :  W H I C H  R E G I M E N  
S H O U L D  B E  A D V I S E D  A S  A D J U V A N T  
O R  N E O A D J U V A N T  C H E M O T H E R A P Y ?
There is no published guidelines on this topic and there is 
no randomised trial comparing the various regimens. There 
is only one meta-analysis [61] performed in advanced disease 
demonstrating better response rates if the number of drugs 
used is higher (3>2>1).
E L C W P  G U I D E L I N E S :
If the patient is treated outside a clinical trial, one of the 
regimens shown to be effective in randomised trials is recom-
mended (level of evidence: experts opinion). It is important to 
perform trials comparing various chemotherapeutic regimens 
as induction treatment and as adjuvant therapy.
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